# UK Medical Cannabis Use: What a New National Survey Found > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/uk-medical-cannabis-prescriptions-high-risk-use/ > **Published:** 2026-07-31T22:06:05-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T22:01:35-04:00 > **Clinical Summary:** Explore UK medical cannabis prescriptions and their association with high-risk use in a new national survey of cannabis users. --- CED Clinical Relevance #72 [Cannabis Science](https://cedclinic.com/biphasic-effects-of-cannabis/) Safety Report A same-day peer-reviewed national survey provides clinically relevant evidence about prescriptions, product sourcing, processed-product use, and screening-positive high-risk use. The cross-sectional design requires careful association-only framing. Clinical Insight | CED Clinic A new UK study examined how people who used cannabis in the prior year described medical use, prescriptions, product sources, and higher-risk patterns. Among 4,414 respondents, prescribed status was associated with more frequent use of several processed products and a higher probability of screening positive for high-risk use. The study does not show that prescriptions caused those patterns. It does show why prescribing conversations should include product source, potency, frequency, adverse effects, and [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) risk. [Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)Patient Safety[Cannabis Use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) DisorderUK SurveyObservational Evidence Audience Patients, caregivers, prescribers, and cannabis-science readers interested in safer [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) use Primary Topic UK [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) prescriptions, product sourcing, and high-risk use Source [Read the full source](https://pubmed.ncbi.nlm.nih.gov/42535284/) A July 31, 2026 national repeat cross-sectional study surveyed 4,414 UK residents who had used cannabis in the prior year. Prescribed respondents more often reported frequent use of several processed products and screening-positive high-risk use. These are associations, not proof that prescribing caused risky use. What This Study Teaches Us Medical use in the UK extends well beyond formal prescribing, and even respondents with prescriptions commonly reported cannabis from additional sources. Prescribed status identified a group with more frequent use of several product types and a higher probability of a positive high-risk-use screen. Why This Matters A prescription does not, by itself, describe the full exposure. Clinicians need to ask about all sources, formulations, potency, frequency, impairment, adverse effects, and signs of [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) rather than treating prescribed status as a complete safety history. Study Snapshot Study Type National repeat cross-sectional surveys conducted in 2023 and 2024 Population 4,414 UK participants aged 16 to 65 who reported [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in the past 12 months Comparison Groups Medical use with a prescription, medical use without a prescription, and no medical use Prescribed Medical Use 12.9% of respondents Medical Use Without Prescription 35.9% of respondents No Medical Use 51.2% of respondents Source Finding Only 10.9% of respondents with prescriptions reported obtaining all cannabis from a prescription Product Finding Prescribed respondents had higher adjusted probabilities of frequent use across several processed product categories High-Risk Screen Prescribed respondents had a higher probability of screening positive for high-risk use, adjusted risk ratio 3.09, 95% CI 2.51 to 3.79 Major Limitation Cross-sectional self-report data cannot establish temporality, causation, or whether prescribing itself changed risk Journal Psychological Medicine Published July 31, 2026 Authors Elle Wadsworth, David Hammond, and Tom P. Freeman PMID / DOI 42535284 / 10.1017/S0033291726105327 Clinical Bottom Line The study supports more complete medical cannabis assessment and counseling, not the claim that prescriptions create high-risk use. What the Study Investigated Researchers analyzed national repeat cross-sectional surveys from 2023 and 2024. Participants were UK residents aged 16 to 65 who reported [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) within the prior 12 months. The analysis compared medical use with a prescription, medical use without a prescription, and nonmedical use. It examined sources, product types, frequent product use, and a screening threshold for high-risk use. What the Survey Found Medical use without a prescription was more common than prescribed medical use in this sample. Among respondents with prescriptions, only 10.9% reported obtaining all cannabis through a prescription. After adjustment, prescribed respondents more often reported frequent use of drops, capsules, vape oils, edibles, drinks, solid concentrates, hash or kief, and topicals. They also had a higher probability of screening positive for high-risk use. Why the Association Is Not Causation The surveys measured exposure and outcomes at the same general time. They cannot establish whether prescribing preceded higher-risk patterns, followed them, or simply identified people with more complex or intensive cannabis use. Self-report, selection into the survey, differences in health status, symptom burden, product access, and other unmeasured factors may influence the observed associations. A Prescription Is Not the Whole Exposure History The sourcing result is clinically important because prescribed patients may also use cannabis obtained elsewhere. Product composition, potency, route, frequency, and labeling may differ across sources. A useful clinical history should therefore cover every cannabis product, not only the prescribed item listed in a medication record. What Clinicians and Patients Can Do Prescribing encounters can include structured discussion of treatment goals, total cannabis exposure, product potency, impairment, tolerance, withdrawal, unsuccessful efforts to reduce use, interactions, and adverse effects. A positive high-risk-use screen is not itself a diagnosis. It is a reason for further assessment, shared decision-making, and proportionate follow-up. How Strong Is This Evidence? The study is peer reviewed, same-day current, nationally framed, includes 4,414 recent cannabis users, and uses adjusted regression to compare clinically meaningful patterns across medical-use groups. Where This Paper Deserves Skepticism The repeat cross-sectional design cannot establish temporality or causation. The findings are based on self-report among people who used cannabis in the prior year, so they should not be generalized to every UK patient or interpreted as an estimate of risk caused by prescribing. What This Paper Does Not Show The study does not prove that a prescription causes [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), show that prescribed products are inherently more dangerous, establish the safety of nonprescribed use, compare treatment effectiveness, or determine which specific product or dose produced harm. How This Fits With the Broader Clinical Conversation Medical and nonmedical cannabis categories can overlap in real life. People may use multiple products for multiple reasons and obtain them through several channels, which complicates both exposure measurement and clinical counseling. Future longitudinal research should measure baseline risk, symptom severity, product potency, dose, source, changes over time, and clinically assessed cannabis use disorder before and after prescribing. Dr. Caplan’s Take *The most useful message is not that prescriptions are dangerous. It is that a prescription label can create false reassurance if the clinician never asks what else the patient is using.* *A careful medical cannabis visit should connect therapeutic goals with a complete product inventory, an impairment and dependence screen, and a plan for monitoring benefit and harm over time.* What a Careful Reader Should Take Away Treat prescribed status as the beginning of the safety history, not the end. Ask about total exposure and interpret a positive risk screen as a prompt for assessment rather than a diagnosis or causal conclusion. Evidence Interpretation Guide Table of Contents - [How to Interpret This UK Medical Cannabis Safety Signal](#How_to_Interpret_This_UK_Medical_Cannabis_Safety_Signal)[A Four-Step Reading Frame](#A_Four-Step_Reading_Frame) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[List Every Product and Source](#List_Every_Product_and_Source) - [Prescribing Needs Active Monitoring](#Prescribing_Needs_Active_Monitoring) - [Selection May Explain Part of the Signal](#Selection_May_Explain_Part_of_the_Signal) - [Screening Is Not Diagnosis](#Screening_Is_Not_Diagnosis) - [Real-World Use Blurs Legal Categories](#Real-World_Use_Blurs_Legal_Categories) - [Ask About Potency, Route, and Function](#Ask_About_Potency_Route_and_Function) - [Longitudinal Evidence Is the Next Step](#Longitudinal_Evidence_Is_the_Next_Step) - [Access and Surveillance Should Develop Together](#Access_and_Surveillance_Should_Develop_Together) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Interpret This UK Medical Cannabis Safety Signal This study identifies a clinically important pattern without proving its cause. The most responsible reading separates what was measured from what still needs longitudinal confirmation. ### A Four-Step Reading Frame **Evidence type**This is a repeat cross-sectional observational study, not a randomized trial or longitudinal causal analysis. **Population**The sample includes UK residents aged 16 to 65 who used cannabis in the prior year, not all UK patients or all prescription recipients. **Outcome meaning**A screening-positive high-risk-use result signals need for assessment; it is not equivalent to a confirmed cannabis use disorder diagnosis. **Clinical use**The findings support fuller product and risk histories during prescribing, while leaving treatment decisions individualized. The Research Question How do prescriptions, cannabis sources, products, and high-risk-use screening differ among UK cannabis users? The Patient Question Does having a prescription mean my complete cannabis use is automatically safe? The Bottom Line Prescribing can support clinical oversight, but safety still depends on the full pattern of products, sources, frequency, effects, and monitoring. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview Eight perspectives help translate this safety signal without turning an observational association into a causal claim. #### List Every Product and Source A prescription may be only one part of a person’s cannabis exposure. Bring a complete list of products, routes, sources, frequency, and effects to clinical visits. Lens takeaway Complete information makes safer shared decisions possible. #### Prescribing Needs Active Monitoring Medication reconciliation should include nonprescribed cannabis and processed products. Screening should be paired with assessment of goals, benefit, impairment, tolerance, withdrawal, and function. Lens takeaway A prescription is a monitoring opportunity, not a guarantee of low risk. #### Selection May Explain Part of the Signal People who obtain prescriptions may have heavier use, greater symptom burden, or more complex histories before prescribing. Cross-sectional adjustment cannot fully resolve those differences. Lens takeaway The adjusted association remains informative but noncausal. #### Screening Is Not Diagnosis A high-risk-use threshold is useful for identifying people who may need further review. It should not be reported as a confirmed disorder without diagnostic assessment. Lens takeaway Use the measure as a flag, not a label. #### Real-World Use Blurs Legal Categories Cannabis exposure often spans multiple products and sources. This study adds current UK data showing why prescribed and nonprescribed use cannot always be treated as separate worlds. Lens takeaway Clinical histories need to reflect how people actually use cannabis. #### Ask About Potency, Route, and Function Product names alone do not define exposure. Useful follow-up includes potency, dose, frequency, driving or work impairment, interactions, and progress toward the treatment goal. Lens takeaway Specific questions produce safer information than a yes-or-no cannabis checkbox. #### Longitudinal Evidence Is the Next Step Researchers need measurements before and after prescribing with repeated assessment over time. Product-level exposure and clinically assessed outcomes would help clarify direction and mechanism. Lens takeaway Temporality is essential for stronger causal inference. #### Access and Surveillance Should Develop Together Legal access can improve oversight only when systems capture real product use and adverse outcomes. Policy should support honest reporting, consistent product information, and nonpunitive clinical screening. Lens takeaway Better access data can strengthen both care and [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/). Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=UK+Medical+Cannabis+Use%3A+What+a+New+National+Survey+Found&url=https%3A%2F%2Fcedclinic.com%2Fuk-medical-cannabis-high-risk-use%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fuk-medical-cannabis-high-risk-use%2F) [BlueSky](https://bsky.app/intent/compose?text=UK+Medical+Cannabis+Use%3A+What+a+New+National+Survey+Found%20https%3A%2F%2Fcedclinic.com%2Fuk-medical-cannabis-high-risk-use%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [The use of cannabis for medical reasons in the UK: Prescriptions, sources, products, and high-risk use.](https://pubmed.ncbi.nlm.nih.gov/42535284/) Related Reading at CED Clinic Continue exploring the evidence [Genetic Pleiotropy Linking Brain Variation to Cannabis Use and Cannabis Use Disorder](https://cedclinic.com/genetic-pleiotropy-differentially-linking-brain-variation-to-cannabis-use-and-cannabis-use-disorder/) Related evidence on the distinction between cannabis use and cannabis use disorder vulnerability. [Review CUD context](https://cedclinic.com/genetic-pleiotropy-differentially-linking-brain-variation-to-cannabis-use-and-cannabis-use-disorder/) [Hazy Science: Study Finds Gaps in Medicinal Cannabis Claims](https://cedclinic.com/hazy-science-study-finds-gaps-in-medicinal-cannabis-claims/) Context for separating medical claims from the quality and limits of the supporting evidence. [Read evidence context](https://cedclinic.com/hazy-science-study-finds-gaps-in-medicinal-cannabis-claims/) [Medical Cannabis Beyond Pain: PM&R Review on Spasticity, Seizures, Sleep and Nausea](https://cedclinic.com/medical-cannabis-non-pain-indications-pmr-review/) A clinical review illustrating why indication, formulation, function, and safety require condition-specific interpretation. [Explore clinical context](https://cedclinic.com/medical-cannabis-non-pain-indications-pmr-review/) ## Frequently Asked Questions Does this study prove that medical cannabis prescriptions cause high-risk use? No. The cross-sectional study found an adjusted association, but it cannot establish which came first or prove causation. How many people were included? The analysis included 4,414 UK participants aged 16 to 65 who reported cannabis use in the prior 12 months. What did the study mean by medical cannabis use? Researchers separated respondents reporting medical use with a prescription, medical use without a prescription, and no medical use. Did everyone with a prescription obtain all cannabis through that prescription? No. Only 10.9% of prescribed respondents reported obtaining all of their cannabis from a prescription. Is a positive high-risk-use screen the same as a cannabis use disorder diagnosis? No. A screening result identifies possible risk and should be followed by appropriate clinical assessment. Which products were more frequently reported by prescribed respondents? The abstract reports higher adjusted probabilities for frequent use of drops, capsules, vape oils, edibles, drinks, solid concentrates, hash or kief, and topicals. Can the findings be generalized outside the UK? Not automatically. Laws, prescribing systems, product markets, and patient populations differ across countries. What should patients discuss with a prescriber? Discuss every cannabis source and product, potency, frequency, treatment goals, benefits, impairment, adverse effects, interactions, tolerance, and withdrawal. What is the study’s biggest limitation? Its cross-sectional self-report design cannot establish temporality or determine whether prescribing changed risk. What is the practical takeaway? Medical cannabis care should include a complete exposure history and ongoing benefit-risk monitoring rather than relying on prescription status alone. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).